Pharmacology · Opioid Research · Review

SR-17018 and the Promise of Biased Agonism: How Selective Signalling May Reduce Tolerance and Withdrawal

A deep dive into the molecular mechanisms behind G protein bias at the μ-opioid receptor, and why SR-17018 has become one of the most studied tool compounds in modern pain pharmacology.
Research use only. SR-17018 is an analytical reference standard and pharmacological tool compound. It is not approved for therapeutic use in any jurisdiction. Nothing in this article constitutes medical advice. All findings described below are derived from preclinical (cell-based and animal model) studies. No human clinical trials have been conducted. Handle with appropriate PPE in a controlled laboratory environment.

The Problem: Why Opioids Stop Working

Classical opioid analgesics like morphine bind to the μ-opioid receptor (MOR) and produce powerful pain relief. But repeated dosing creates a vicious feedback loop: the body adapts, the drug loses potency, and the patient needs escalating doses to achieve the same effect. This is tolerance. When the drug is withdrawn, the now-adapted system overshoots in the opposite direction, producing nausea, pain hypersensitivity, anxiety, and autonomic instability. This is withdrawal.

For decades, tolerance and withdrawal were considered inseparable from opioid analgesia. The receptor that kills pain was assumed to be the same receptor that causes dependence. But a growing body of research suggests this assumption is wrong, or at least incomplete. The key insight is that what matters is not which receptor is activated, but how it is activated.

Two Roads from One Receptor

When an agonist binds to the μ-opioid receptor, the receptor does not simply switch on. It undergoes a conformational change that can engage two fundamentally different intracellular signalling cascades. Think of the receptor as a lever that can tilt in two directions, each activating a different downstream machine.

μ-Opioid Receptor G Protein (Gαi/o) DESIRED EFFECTS Analgesia (pain relief) Reduced neuronal excitability Ion channel modulation GIRK channel activation β-Arrestin-2 ADVERSE EFFECTS Respiratory depression Receptor desensitisation Tolerance development Constipation preferred by SR-17018 recruited by morphine BIASED AGONISM = SEPARATING PAIN RELIEF FROM SIDE EFFECTS
Figure 1

The μ-opioid receptor can signal through two major pathways. G protein coupling (left, green) drives analgesia. β-Arrestin-2 recruitment (right, red) is associated with receptor internalisation, tolerance, and several adverse effects. SR-17018 preferentially activates the G protein arm while minimally engaging β-arrestin-2.

Pathway 1: G Protein Signalling (The Good)

The first pathway involves coupling to inhibitory G proteins (Gαi/o). When the receptor activates these proteins, a cascade follows: adenylyl cyclase is inhibited, cyclic AMP levels drop, potassium channels open (GIRK channels), and calcium channels close. The net result is that pain-transmitting neurons become less excitable. This is analgesia.

Pathway 2: β-Arrestin-2 Recruitment (The Bad)

The second pathway involves a scaffolding protein called β-arrestin-2. After the receptor fires, β-arrestin-2 is recruited to the intracellular face of the receptor. Its original function is housekeeping: it desensitises the receptor and triggers internalisation. But research over the past two decades has implicated β-arrestin-2 in a broader and more troubling set of consequences, including the development of analgesic tolerance, respiratory depression, and gastrointestinal dysfunction.

The hypothesis, first articulated clearly by Laura Bohn and colleagues in the early 2000s using β-arrestin-2 knockout mice, is elegant: if you could design a drug that activates the G protein pathway without recruiting β-arrestin-2, you might get the pain relief without the tolerance and many of the side effects.

This is the concept of biased agonism, and SR-17018 is one of the most potent and well-characterised biased agonists developed to test it.

SR-17018: The Compound

SR-17018 was first reported in the landmark 2017 paper by Schmid, Kennedy, Ross and colleagues, published in Cell. The study screened a library of MOR agonists and measured their relative activation of G protein versus β-arrestin-2 pathways. From this screen, SR-17018 emerged as the compound with the highest G protein bias factor, approximately 80 to 100-fold relative to the reference agonist DAMGO.

In plain language: SR-17018 activates the μ-opioid receptor's G protein machinery roughly 80 to 100 times more potently than it recruits β-arrestin-2, compared to a balanced agonist. Morphine, by contrast, recruits both pathways much more equally.

G PROTEIN BIAS FACTOR (RELATIVE TO DAMGO) 0 20 40 60 80 100 DAMGO (ref = 1) 1x Morphine ~5x TRV130 (oliceridine) ~10x SR-17018 80-100x Highest bias in the Schmid et al. screen
Figure 2

Comparison of G protein bias factors for selected MOR agonists, relative to the reference agonist DAMGO. SR-17018 shows dramatically higher selectivity for G protein signalling over β-arrestin-2 recruitment compared to morphine or oliceridine (TRV130). Values are approximate, derived from Schmid et al. (2017), Cell.

How SR-17018 May Reduce Tolerance

The tolerance-reduction hypothesis rests on three interconnected mechanisms, each supported by preclinical evidence from the studies published between 2017 and 2024.

1

Reduced receptor desensitisation. β-Arrestin-2 physically caps the activated receptor, terminating signalling and initiating internalisation. With less β-arrestin-2 recruitment, the receptor remains in its active, signalling-competent state for longer. Gillis et al. (2021) showed that SR-17018 produces an atypical phosphorylation pattern on the receptor's C-terminal tail.

2

Reduced receptor internalisation. Normally, β-arrestin-2 mediates clathrin-dependent endocytosis of the receptor. Fewer receptors are pulled off the cell surface, so the total number of available (surface) receptors remains higher over time.

3

Sustained G protein activation without compensatory upregulation. Stahl et al. (2021, PNAS) demonstrated that SR-17018 produces sustained G protein activation even after washout, behaving as a "noncompetitive" agonist. This sustained activation did not provoke the same degree of compensatory adenylyl cyclase superactivation that drives both tolerance and withdrawal.

MORPHINE vs SR-17018: RECEPTOR FATE OVER REPEATED DOSING MORPHINE (Balanced Agonist) DOSE 1 Receptor fires → G protein + β-arr2 Strong analgesia REPEATED DOSES β-arr2 desensitises receptor Receptor internalised ↓ surface MOR ADAPTATION cAMP superactivation (compensatory) Need higher dose = TOLERANCE DRUG REMOVED Unopposed cAMP overshoot = WITHDRAWAL SR-17018 (G Protein Biased) DOSE 1 Receptor fires → G protein only Analgesia (comparable) REPEATED DOSES Minimal β-arr2 → less desensitisation Receptors stay on surface SUSTAINED USE Reduced cAMP superactivation Stable efficacy = LESS TOLERANCE DRUG REMOVED Smaller cAMP rebound = REDUCED WITHDRAWAL Less β-arrestin-2 → less desensitisation → less compensatory adaptation → less tolerance & withdrawal
Figure 3

Simplified comparison of receptor-level events during chronic exposure to a balanced agonist (morphine, left) versus a G protein-biased agonist (SR-17018, right). The critical divergence occurs at the β-arrestin-2 recruitment step.

The Evidence: What the Studies Show

Schmid et al. (2017), Cell

The foundational study. The authors screened a panel of MOR agonists and found that compounds with higher G protein bias factors correlated with wider "therapeutic windows" between analgesia and respiratory depression in mouse models. SR-17018, with the highest bias factor, showed the widest window.

Grim et al. (2020), Neuropsychopharmacology

This study directly tested the tolerance-and-withdrawal hypothesis. Mice treated chronically with SR-17018 showed significantly less analgesic tolerance compared to morphine-treated mice. Crucially, SR-17018 could reverse already-established morphine tolerance, suggesting it may have utility not only as a first-line compound but as an intervention for existing opioid dependence.

Stahl et al. (2021), PNAS

SR-17018 acts as a "noncompetitive" agonist at the G protein level. Unlike morphine, which produces a transient burst of G protein activity, SR-17018 produces a sustained, lower-amplitude signal that persists even after washout. This sustained but moderate activation may be the mechanistic basis for reduced tolerance.

Gillis et al. (2021), Molecules

SR-17018 produces a distinct pattern of receptor phosphorylation compared to morphine or DAMGO. Specific serine and threonine residues that normally serve as docking sites for β-arrestin-2 were phosphorylated weakly or not at all.

Pantouli et al. (2021), Neuropharmacology

A head-to-head comparison in multiple mouse pain models. SR-17018 showed comparable acute analgesic efficacy to morphine but with significantly reduced tolerance development over a seven-day chronic dosing regimen. However, it did develop tolerance in the tail immersion assay, demonstrating that the tolerance profile is assay-dependent.

Singleton et al. (2024), Neuropharmacology

The most recent mechanistic study demonstrated that SR-17018 activates the μ-opioid receptor through a conformationally distinct mechanism, further distinguishing it from conventional full agonists.

Important caveat Ding et al. (2023, The Journal of Pain) reported that SR-17018 showed low in vivo efficacy in non-human primate models, raising questions about whether the strong mouse-model results will translate to higher species. This does not invalidate the biased agonism hypothesis, but it underscores that species differences may significantly affect outcomes.

Open Questions and Limitations

QuestionCurrent status
Does high G protein bias translate to higher species?Ding et al. (2023) showed low efficacy in non-human primates.
Is β-arrestin-2 really the "bad actor"?Some labs have challenged the original knockout data. Debate is ongoing.
Could the bias be context-dependent?Singleton et al. (2024) suggest SR-17018 activates MOR through a distinct conformational mechanism.
Can bias be maintained across dose ranges?Some evidence suggests that at very high concentrations, even biased agonists may recruit β-arrestin-2.

Why SR-17018 Matters as a Research Tool

Regardless of whether SR-17018 itself ever becomes a therapeutic candidate, its value to the field is already established. It provides researchers with a high-bias-factor probe compound that can be used to dissect the relative contributions of G protein and β-arrestin pathways. The broader lesson of biased agonism extends well beyond opioids, transforming how pharmacologists think about drug design across GPCRs.

Reminder. SR-17018 is sold exclusively as an analytical reference standard for in vitro laboratory research, forensic analysis, and pharmacological investigation. It is not a food, supplement, cosmetic, or therapeutic agent. No therapeutic claims are made.

References

  1. 1. Schmid CL, Kennedy NM, Ross NC, et al. Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics. Cell. 2017;171(5):1165-1175.e13. doi:10.1016/j.cell.2017.10.035
  2. 2. Grim TW, Schmid CL, Stahl EL, et al. A G Protein Signalling-Biased Agonist at the μ-Opioid Receptor Reverses Morphine Tolerance While Preventing Withdrawal. Neuropsychopharmacology. 2020;45:416-425.
  3. 3. Pantouli F, et al. Comparison of Morphine, Oxycodone and the Biased MOR Agonist SR-17018. Neuropharmacology. 2021;185:108439.
  4. 4. Stahl EL, et al. G Protein Signalling-Biased MOR Agonists That Produce Sustained G Protein Activation Are Noncompetitive Agonists. PNAS. 2021;118(46):e2102178118.
  5. 5. Gillis A, et al. SR-17018 Stimulates Atypical μ-Opioid Receptor Phosphorylation and Dephosphorylation. Molecules. 2021;26(15):4509.
  6. 6. Ding H, et al. G Protein-Biased MOR Agonist SR-17018 Has Low In Vivo Efficacy in Non-Human Primates. The Journal of Pain. 2023;24(8):1479-1490.
  7. 7. Singleton S, et al. Activation of μ Receptors by SR-17018 Through a Distinctive Mechanism. Neuropharmacology. 2024;253:109973.